High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

Jean El-Cheikh, Mauricette Michallet, Arnon Nagler, Hugues De Lavallade, Franck E. Nicolini, Avichai Shimoni, Catherine Faucher, Mohamad Sobh, Daniela Revesz, Izhar Hardan, Sabine Fürst, Didier Blaise, Mohamad Mohty*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We describe the results of 37 myeloma patients who received bortezomib following reduced intensity allogeneic stem cell transplantation (RIC-allo-SCT). Grade 1-2 peripheral neuropathy (35%), mild thrombocytopenia (24%) and fatigue (19%) were the most frequent adverse events, while there was no worsening of graft-vs-host disease symptoms. Twenty-seven patients (73%; 95% CI, 59-87%) achieved an objective response. With a median follow-up of 9 months from bortezomib initiation, the estimate of overall survival was 65% at 18 months while this was significantly higher (p=0.002) in the 27 patients achieving an objective response, suggesting that bortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT.

Original languageEnglish
Pages (from-to)455-458
Number of pages4
JournalHaematologica
Volume93
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Keywords

  • Allogeneic stem cell transplantation
  • Bortezomib
  • Multiple myeloma

Fingerprint

Dive into the research topics of 'High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma'. Together they form a unique fingerprint.

Cite this